Ashley Cimino-Mathews

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Breast 48%
3. Tumor-Infiltrating Lymphocytes 42%
4. Neoplasms 39%
5. Carcinoma 31%
6. Estrogen Receptors 29%
7. Triple Negative Breast Neoplasms 23%
8. Immunohistochemistry 22%
9. Large-Core Needle Biopsy 21%
10. Neoplasm Metastasis 20%
11. Carcinoma, Intraductal, Noninfiltrating 18%
12. Ductal Carcinoma 18%
13. Progesterone Receptors 15%
14. Biomarkers 14%
15. Tumor Microenvironment 14%
16. Phyllodes Tumor 14%
17. Fibroepithelial Neoplasms 14%
18. durvalumab 13%
19. Poly(ADP-ribose) Polymerase Inhibitors 12%
20. Recurrence 12%
21. Fine Needle Biopsy 11%
22. olaparib 11%
23. Biopsy 9%
24. Uroplakin II 9%
25. Lymph Nodes 9%
26. Ligands 9%
27. Mammography 9%
28. cediranib 8%
29. Survival 8%
30. Neoadjuvant Therapy 8%
31. Trastuzumab 8%
32. Differential Diagnosis 8%
33. pertuzumab 8%
34. Nerve Sheath Neoplasms 7%
35. Fluorescence In Situ Hybridization 7%
36. Immunotherapy 7%
37. Therapeutics 7%
38. Adenoid Cystic Carcinoma 7%
39. Adenocarcinoma 7%
40. Fibroadenoma 7%
41. Inflammatory Breast Neoplasms 7%
42. Ovarian Neoplasms 7%
43. prexasertib 7%
44. Pathology 7%
45. Whole Exome Sequencing 7%
46. Pleomorphic Adenoma 6%
47. Neurilemmoma 6%